Explore the latest developments showcased at World ADC, highlighting smarter payloads and precise targeting in drug discovery.

Pharma-biotech pairings continued apace in the antibody-drug conjugate (ADC) space, with 2023 capped by Legochem Biosciences Inc. signing a $1.7 billion licensure deal with Johnson & Johnson arm ...

Synaffix, a Lonza company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs), licensed its ADC technology to BigHat Biosciences ...

Antibody-drug conjugates (ADCs) have emerged as a promising approach in cancer therapy, offering a 'magic bullet' strategy that combines the precision of monoclonal antibodies with the potency of ...

Dr. Paolo Tarantino shares how antibody-drug conjugates deliver more targeted chemo, and how the treatment lasts longer in the body vs traditional therapy. Antibody-drug conjugates (ADCs) are changing ...

Commercial license to Synaffix technologies follows a series of successful initial preclinical proof of concept studies Collaboration underscores Lonza's commitment to helping customers deliver ...